FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2078140185> ?p ?o ?g. }

• W2078140185 endingPage "263" @default.
• W2078140185 startingPage "254" @default.
• W2078140185 abstract "Background The magnitude of benefit of trastuzumab for the treatment of advanced HER2-positive breast cancer varies widely. In this retrospective study, we investigated the clinicopathological features associated with prolonged first-line trastuzumab-based treatment duration. Patients and Methods A total of 164 patients diagnosed with advanced HER2-positive breast cancer and treated with first-line trastuzumab-based therapy from 1999 to 2009 were identified. Duration of treatment was classified according to tertiles. Different logistic regression models including age, disease-free interval, number of metastatic sites, visceral disease, hormone receptor, and adjuvant trastuzumab were fitted to investigate associations with benefit of prolonged trastuzumab-based therapies. The predictive value of each model was assessed using C-statistics. Results At a median follow-up of 5.8 years (range, 0.7-22.1 years), patients in the short-, intermediate-, and long-term treatment duration groups were given first-line trastuzumab-based therapy for < 7.2 months, 7.2 to 14 months, and > 14 months, respectively. In the multivariate analysis, patients with long-term clinical benefit had a higher likelihood of having hormone receptor-positive tumors (odds ratio [OR]positive vs. negative = 2.39 [95% confidence interval (CI), 1.08-5.31]; P = .032); and a lower likelihood of having received adjuvant trastuzumab (ORadjuvant trastuzumab vs. no adjuvant trastuzumab = 0.30 [95% CI, 0.10-0.96]; P = .043]. C-statistics varied between 0.634 and 0.699. Conclusion Long-term benefit of trastuzumab-based therapy is associated with hormone receptor positivity and the absence of previous adjuvant trastuzumab. Nevertheless, clinicopathological features had a low predictive value for prolonged treatment duration. The validation of the current findings and the identification of molecular features associated the magnitude of trastuzumab benefit should be encouraged." @default.
• W2078140185 created "2016-06-24" @default.
• W2078140185 creator A5032785430 @default.
• W2078140185 creator A5038599053 @default.
• W2078140185 creator A5040999127 @default.
• W2078140185 creator A5049174232 @default.
• W2078140185 creator A5055301443 @default.
• W2078140185 creator A5057281656 @default.
• W2078140185 creator A5068721624 @default.
• W2078140185 creator A5070245248 @default.
• W2078140185 creator A5078684653 @default.
• W2078140185 creator A5081556991 @default.
• W2078140185 creator A5087875043 @default.
• W2078140185 date "2013-08-01" @default.
• W2078140185 modified "2023-09-27" @default.
• W2078140185 title "Clinicopathological Features Among Patients With Advanced Human Epidermal Growth Factor–2-Positive Breast Cancer With Prolonged Clinical Benefit to First-Line Trastuzumab-Based Therapy: A Retrospective Cohort Study" @default.
• W2078140185 cites W1510554288 @default.
• W2078140185 cites W1546709038 @default.
• W2078140185 cites W1644299043 @default.
• W2078140185 cites W2000269004 @default.
• W2078140185 cites W2028457403 @default.
• W2078140185 cites W2034414538 @default.
• W2078140185 cites W2035484878 @default.
• W2078140185 cites W2057388131 @default.
• W2078140185 cites W2066772614 @default.
• W2078140185 cites W2074819793 @default.
• W2078140185 cites W2097255042 @default.
• W2078140185 cites W2106292881 @default.
• W2078140185 cites W2108863890 @default.
• W2078140185 cites W2114080253 @default.
• W2078140185 cites W2115759102 @default.
• W2078140185 cites W2121593217 @default.
• W2078140185 cites W2124570421 @default.
• W2078140185 cites W2131994307 @default.
• W2078140185 cites W2135548733 @default.
• W2078140185 cites W2141393790 @default.
• W2078140185 cites W2141929347 @default.
• W2078140185 cites W2144686284 @default.
• W2078140185 cites W2149773268 @default.
• W2078140185 cites W2157840751 @default.
• W2078140185 cites W2159459001 @default.
• W2078140185 cites W2160928966 @default.
• W2078140185 cites W2166199281 @default.
• W2078140185 cites W2166311434 @default.
• W2078140185 cites W2318605753 @default.
• W2078140185 doi "https://doi.org/10.1016/j.clbc.2013.02.010" @default.
• W2078140185 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4084778" @default.
• W2078140185 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23829891" @default.
• W2078140185 hasPublicationYear "2013" @default.
• W2078140185 type Work @default.
• W2078140185 sameAs 2078140185 @default.
• W2078140185 citedByCount "24" @default.
• W2078140185 countsByYear W20781401852014 @default.
• W2078140185 countsByYear W20781401852015 @default.
• W2078140185 countsByYear W20781401852016 @default.
• W2078140185 countsByYear W20781401852017 @default.
• W2078140185 countsByYear W20781401852018 @default.
• W2078140185 countsByYear W20781401852019 @default.
• W2078140185 countsByYear W20781401852020 @default.
• W2078140185 countsByYear W20781401852021 @default.
• W2078140185 crossrefType "journal-article" @default.
• W2078140185 hasAuthorship W2078140185A5032785430 @default.
• W2078140185 hasAuthorship W2078140185A5038599053 @default.
• W2078140185 hasAuthorship W2078140185A5040999127 @default.
• W2078140185 hasAuthorship W2078140185A5049174232 @default.
• W2078140185 hasAuthorship W2078140185A5055301443 @default.
• W2078140185 hasAuthorship W2078140185A5057281656 @default.
• W2078140185 hasAuthorship W2078140185A5068721624 @default.
• W2078140185 hasAuthorship W2078140185A5070245248 @default.
• W2078140185 hasAuthorship W2078140185A5078684653 @default.
• W2078140185 hasAuthorship W2078140185A5081556991 @default.
• W2078140185 hasAuthorship W2078140185A5087875043 @default.
• W2078140185 hasBestOaLocation W20781401852 @default.
• W2078140185 hasConcept C121608353 @default.
• W2078140185 hasConcept C126322002 @default.
• W2078140185 hasConcept C143998085 @default.
• W2078140185 hasConcept C156957248 @default.
• W2078140185 hasConcept C167135981 @default.
• W2078140185 hasConcept C2777982462 @default.
• W2078140185 hasConcept C2779786085 @default.
• W2078140185 hasConcept C44249647 @default.
• W2078140185 hasConcept C530470458 @default.
• W2078140185 hasConcept C71924100 @default.
• W2078140185 hasConceptScore W2078140185C121608353 @default.
• W2078140185 hasConceptScore W2078140185C126322002 @default.
• W2078140185 hasConceptScore W2078140185C143998085 @default.
• W2078140185 hasConceptScore W2078140185C156957248 @default.
• W2078140185 hasConceptScore W2078140185C167135981 @default.
• W2078140185 hasConceptScore W2078140185C2777982462 @default.
• W2078140185 hasConceptScore W2078140185C2779786085 @default.
• W2078140185 hasConceptScore W2078140185C44249647 @default.
• W2078140185 hasConceptScore W2078140185C530470458 @default.
• W2078140185 hasConceptScore W2078140185C71924100 @default.
• W2078140185 hasIssue "4" @default.
• W2078140185 hasLocation W20781401851 @default.
• W2078140185 hasLocation W20781401852 @default.
• W2078140185 hasLocation W20781401853 @default.
• W2078140185 hasLocation W20781401854 @default.

• next